Cone-Shaped Cationic Lipids for Stable mRNA LNP Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid-based therapeutics face challenges such as degradation by nucleases, limited cellular uptake, and inefficient gene expression, necessitating the development of mRNA-LNPs with enhanced biocompatibility, stability, and safety for effective delivery.
Innovation Solution
A new class of cationic lipid compounds with a cone-shaped structure and hydroxyl group at the head, featuring degradable ester bonds, is synthesized to enhance biocompatibility and mRNA transfection efficiency, forming LNPs with stable nanostructures for safe and effective delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid molecules are used for gene delivery, then therapeutic effect can be achieved, but they are easily degraded by nucleases in vivo and in vitro
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to protect nucleic acid molecules from nuclease degradation. The lipid bilayer structure of LNPs encapsulates the nucleic acid payload, creating a physical barrier that prevents contact with nucleases in the biological environment, thereby resolving the contradiction between achieving therapeutic effect and avoiding degradation.
Solution Approach 2:
The patent modifies the chemical structure of lipid molecules by introducing degradable ester bonds at specific positions (M2 and M3 in the general formula). This parameter change allows the LNP structure to be stable during delivery but degrade controllably after cellular uptake, protecting nucleic acids from degradation while enabling eventual release of the therapeutic payload.
2Reliability
If nucleic acid molecules are used for gene delivery, then gene expression can be regulated, but the ability to enter cells is limited
Solution Approach 1:
The patent modifies the lipid structure by incorporating ionizable amine groups that can be protonated at acidic pH. This parameter change enables the LNP to interact with negatively charged cell membranes and undergo endosomal escape, significantly improving cellular uptake efficiency while maintaining the ability to deliver and express therapeutic genes.
Solution Approach 2:
The patent creates composite lipid nanoparticle structures combining ionizable lipids with helper lipids, cholesterol, and PEGylated lipids. This composite material approach enhances cellular uptake through multiple mechanisms including membrane interaction, endosomal disruption, and sustained circulation, thereby resolving the contradiction between gene expression capability and cellular entry efficiency.
3Productivity
If cationic lipid compounds are used to enhance mRNA transfection efficiency, then delivery effectiveness improves, but biosafety concerns may arise
Solution Approach 1:
The patent introduces degradable ester bonds at positions M2 and M3 of the lipid structure, creating a parameter change that enables controlled degradation of the cationic lipid after delivering its function. This allows high transfection efficiency during delivery while ensuring the lipid breaks down into harmless components afterward, resolving the contradiction between productivity and biosafety.
Solution Approach 2:
The patent designs the cationic lipid as a disposable carrier that performs its delivery function and then degrades. The degradable ester bonds ensure the lipid structure is temporary and self-limiting, providing high transfection efficiency during its functional lifetime while automatically eliminating safety concerns after use through metabolic degradation.
Data Source
AI summary
A cationic lipid compound, and a preparation method therefor and use thereof are provided. The cationic lipid compound features a hydroxyl group at the head part, and its overall structure resembles a cone with a small head and a large tail. The LNPs prepared using the cationic lipid compounds with the aforementioned optimal structure usually exhibit enhanced biocompatibility and higher in vivo mRNA transfection efficiency, achieving unexpected technical effects. The synthesis route of the cationic lipid compounds is straightforward and practicable, with inexpensive and readily available raw materials, facilitating industrial production. Furthermore, the LNPs produced from the cationic lipid compounds possess a stable nanostructure that can be stored at low temperatures for a long time, thereby prolonging the shelf life of the pharmaceutical products while reducing the transportation requirements.